Understand the market access strategies of pharma innovators
Gain immediate access to 4 in-depth market access reports spotlighting groundbreaking therapies shaping the future of healthcare. Explore insights into their market size and growth potential, competitive dynamics and pricing strategies.
What you’ll get:
- Expert analysis on the market access landscape around innovative new medicines.
- Key data points and trends driving market access decisions.
- Actionable intelligence for strategic planning.
Download all 4 reports in one click
What’s inside the reports
Casgevy & Lyfgenia
Casgevy™ and Lyfgenia™ are the first FDA-approved cell-based gene therapies for sickle cell disease (SCD), and they come with multimillion-dollar list prices, posing a test for payers – and for the U.S. government’s new voluntary outcomes-based Cell and Gene Therapy Access Model. This report examines the market access landscape surrounding these therapeutics including market share growth, cost and coverage challenges, physician perceptions and much more.
Arexvy & Abrysvo
Arexvy™ and Abrysvo™ are the first FDA-approved RSV vaccines for high-risk populations: older adults and infants. This report explores the RSV disease landscape including competitive considerations, potential market barriers, market size and share, patient perspectives and much more.
Eylea® HD
Eylea HD is a high-dose version of aflibercept, a blockbuster drug for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and related conditions of the retina. In an effort to fend off competition from biosimilar drugs, Regeneron released Eylea HD (8mg) in anticipation of its Eylea (2mg) 2025 patent expiration. This report explores the disease landscape, pricing strategy, market size and growth potential, physician and patient perspectives and much more.
Tarpeyo / Kinpeygo
Tarpeyo®/Kinpeygo® are the first FDA-approved treatments for immunoglobulin A nephropathy (IgAN), a rare kidney disease, granted accelerated approval in 2021 based on a surrogate endpoint. Initially approved with a limited indication, it was later expanded after follow-up clinical trial data. However, the drug’s high price presents a potential hurdle to broad market acceptance. In this report, learn more about the disease’s competitive landscape, adverse events, pricing considerations and much more.
